Navigation Links
Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche
Date:5/25/2011

AUSTIN, Texas, May 25, 2011 /PRNewswire/ -- Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova's biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.

"Achieving this milestone is an example of how pharmaceutical and biotechnology companies can leverage RBM's testing services, databases, and expertise to make real progress," said Craig Benson, President and CEO of RBM. "We appreciate the opportunity to work with a company of Roche's stature and experience to develop a product that both meets Roche's needs and can potentially improve patient outcomes. RBM values this relationship with a company that is leading the way and shares our vision for personalized healthcare"

This project highlights Rules-Based Medicine's Strategic Biomarker Services. RBM consults with our partners to design the best clinical trial, using our comprehensive menu of quantitative immunoassays and decades of expertise in sample type selection, experimental design, and data analysis.

On April 27, 2011, Myriad Genetics (Nasdaq: MYGN) of Salt Lake City, a leader in molecular diagnostics, announced an agreement to acquire Rules-Based Medicine. The transaction is expected to be complete by May 31, 2011. RBM headquarters will remain in Austin, TX and will operate as a wholly owned subsidiary of Myriad Genetics under the name Myriad RBM.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at www.rulesbasedmedicine.com.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
2. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
3. Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
4. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
5. Particle trap paves way for personalized medicine
6. ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
7. Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine
8. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
9. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
10. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine
11. Aesthetic Plastic Surgery and Anti Aging Medicine Symposium Features New Developments in the Science of Stem Cells and Fat Grafting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... coverage option for U.S. consumers who want to have ... DarioHealth has signed strategic alliance agreements with partners across ... coverage benefits, and if approved, will supply and bill ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research ... Stem Cell (hESC) Research - Global Strategic Business Report" report ... ... Cell (hESC) Research in US$ Million. Annual estimates and forecasts are ... are derived from primary and secondary research. The ...
(Date:3/24/2017)... Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company ... vaccines, today announced participation at the following conferences: ... and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at ... New York, NY . Agenus will participate in ... am: Robert B. Stein , M.D., Ph.D., President, ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
Breaking Biology Technology:
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):